3170-0014 30-day FRN (published)

13278

Federal Register / Vol. 87, No. 46 / Wednesday, March 9, 2022 / Notices

Dated: March 4, 2022.
Tracey L. Thompson,
Acting Deputy Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2022–05002 Filed 3–8–22; 8:45 am]
BILLING CODE 3510–22–P

DEPARTMENT OF COMMERCE

Robert Bahr,
Deputy Commissioner for Patents, United
States Patent and Trademark Office.

Patent and Trademark Office
[Docket No. PTO–P–2022–0009]

[FR Doc. 2022–04969 Filed 3–8–22; 8:45 am]

Grant of Interim Extension of the Term
of U.S. Patent No. 8,858,612; Reducer®

BILLING CODE 3510–16–P

United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.

DEPARTMENT OF COMMERCE

AGENCY:

Patent and Trademark Office

VerDate Sep<11>2014

17:44 Mar 08, 2022

Jkt 256001

United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:

The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 6,953,476.
FOR FURTHER INFORMATION CONTACT: Ali
Salimi, Senior Legal Advisor, Office of
Patent Legal Administration, by
telephone at 571–272–0909 or by email
to ali.salimi@uspto.gov.
SUPPLEMENTARY INFORMATION: Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On February 22, 2022, Neovasc
Medical Ltd., the patent owner of
record, timely filed an application
under 35 U.S.C. 156(d)(5) for a third
interim extension of the term of U.S.
Patent No. 6,953,476. The patent claims
a catheter delivered implantable device,
Reducer®. The application for patent
term extension indicates that a
Premarket Approval Application (PMA)
P190035 was submitted to the Food and
Drug Administration (FDA) on
December 31, 2019. Review of the
patent term extension application
indicates that, except for permission to
market or use the product commercially,
the subject patent would be eligible for

PO 00000

Frm 00028

Fmt 4703

Sfmt 4703

Robert Bahr,
Deputy Commissioner for Patents, United
States Patent and Trademark Office.
BILLING CODE 3510–16–P

Grant of Interim Extension of the Term
of U.S. Patent No. 6,953,476; Reducer®

SUMMARY:

an extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because the
regulatory review period will continue
beyond the extended expiration date of
the patent, March 27, 2022, interim
extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
6,953,476 is granted for a period of one
year from the extended expiration date
of the ’476 patent.

[FR Doc. 2022–04970 Filed 3–8–22; 8:45 am]

[Docket No.: PTO–P–2022–0003]

The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 8,858,612.
FOR FURTHER INFORMATION CONTACT: Ali
Salimi, Senior Legal Advisor, Office of
Patent Legal Administration, by
telephone at 571–272–0909 or by email
to ali.salimi@uspto.gov.
SUPPLEMENTARY INFORMATION: Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On February 22, 2022, Neovasc
Medical Ltd., the patent owner of
record, timely filed an application
under 35 U.S.C. 156(d)(5) for a third
interim extension of the term of U.S.
Patent No. 8,858,612. The patent claims
methods of using a catheter delivered
implantable device known by the
tradename Reducer®. The application
for patent term extension indicates that
a Premarket Approval Application
(PMA) P190035 was submitted to the
Food and Drug Administration (FDA) on
December 31, 2019.
Review of the patent term extension
application indicates that, except for
permission to market or use the product
commercially, the subject patent would
be eligible for an extension of the patent
term under 35 U.S.C. 156, and that the
patent should be extended for one year
as required by 35 U.S.C. 156(d)(5)(B).
Because the regulatory review period
will continue beyond the extended
expiration date of the patent, March 27,
SUMMARY:

jspears on DSK121TN23PROD with NOTICES1

2022, interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
8,858,612 is granted for a period of one
year from the extended expiration date
of the ’612 patent.

BUREAU OF CONSUMER FINANCIAL
PROTECTION
[Docket No. CFPB–2022–0017]

Agency Information Collection
Activities: Comment Request
Bureau of Consumer Financial
Protection.
ACTION: Notice and request for comment.
AGENCY:

In accordance with the
Paperwork Reduction Act of 1995
(PRA), the Consumer Financial
Protection Bureau (CFPB or Bureau)
requests the extension of the Office of
Management and Budget’s (OMB’s)
approval of the existing information
collection titled ‘‘Electronic Fund
Transfer Act (Regulation E)’’ approved
under OMB Control Number 3170–0014.
DATES: Written comments are
encouraged and must be received on or
before April 8, 2022 to be assured of
consideration.
SUMMARY:

Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. In general, all
comments received will become public
records, including any personal
information provided. Sensitive
personal information, such as account
numbers or Social Security numbers,
should not be included.
FOR FURTHER INFORMATION CONTACT:
Documentation prepared in support of
this information collection request is
available at www.regulations.gov.
Requests for additional information
ADDRESSES:

E:\FR\FM\09MRN1.SGM

09MRN1

jspears on DSK121TN23PROD with NOTICES1

Federal Register / Vol. 87, No. 46 / Wednesday, March 9, 2022 / Notices
should be directed to Anthony May,
Paperwork Reduction Act Officer, at
(202) 841–0544, or email: CFPB_PRA@
cfpb.gov. If you require this document
in an alternative electronic format,
please contact CFPB_Accessibility@
cfpb.gov. Please do not submit
comments to these email boxes.
SUPPLEMENTARY INFORMATION:
Title of Collection: Electronic Fund
Transfer Act (Regulation E).
OMB Control Number: 3170–0014.
Type of Review: Extension of a
currently approved information
collection.
Affected Public: Businesses and other
for-profit institutions.
Estimated Number of Respondents:
600,000.
Estimated Total Annual Burden
Hours: 3,361,056.
Abstract: The Electronic Fund
Transfer Act (EFTA), 15 U.S.C. 1693 et
seq., requires accurate disclosure of the
costs, terms, and rights relating to
electronic fund transfer (EFT) services
and remittance transfer services to
consumers. Entities offering EFT
services must provide consumers with
full and accurate information regarding
consumers’ rights and responsibilities in
connection with EFT services. These
disclosures are intended to protect the
rights of consumers using EFT services,
such as automated teller machine
(ATM) transfers, telephone bill-payment
services, point-of-sale transfers at retail
establishments, electronic check
conversion, payroll cards, and
preauthorized transfers from or to a
consumer’s account. EFTA also
establishes error resolution procedures
and limits consumer liability for
unauthorized transfers in connection
with EFT services. EFTA and Regulation
E impose disclosure and other
requirements on issuers and sellers of
gift cards, gift certificates, and generaluse prepaid cards. Further, EFTA and
Regulation E provide protections for
consumers in the United States who
send remittance transfers to persons in
a foreign country. It also provides
comprehensive protections for
consumers who use ‘‘prepaid accounts.’’
Tailored provisions governing
disclosures, limited liability, error
resolution, and periodic statements
added new requirements regarding the
posting of account agreements.
Additionally, Regulations E regulates
overdraft credit features offered in
connection with prepaid accounts.
Request for Comments: The Bureau
published a 60-day Federal Register
notice on 12/16/2021 (86 FR 71453)
under Docket Number: CFPB–2021–
0021. The Bureau is soliciting

VerDate Sep<11>2014

17:44 Mar 08, 2022

Jkt 256001

comments on: (a) Whether the collection
of information is necessary for the
proper performance of the functions of
the Bureau, including whether the
information will have practical utility;
(b) The accuracy of the Bureau’s
estimate of the burden of the collection
of information, including the validity of
the methods and the assumptions used;
(c) Ways to enhance the quality, utility,
and clarity of the information to be
collected; and (d) Ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Comments submitted in
response to this notice will be submitted
to OMB as part of its review of this
request. All comments will become a
matter of public record.
Anthony May,
Paperwork Reduction Act Officer, Consumer
Financial Protection Bureau.
[FR Doc. 2022–04953 Filed 3–8–22; 8:45 am]
BILLING CODE 4810–AM–P

DEPARTMENT OF DEFENSE
Office of the Secretary
Defense Health Board; Notice of
Federal Advisory Committee Meeting
Under Secretary of Defense for
Personnel and Readiness, Department of
Defense (DoD).
ACTION: Notice of Federal Advisory
Committee meeting.
AGENCY:

The DoD is publishing this
notice to announce that the following
Federal Advisory Committee meeting of
the Defense Health Board (DHB) will
take place.
DATES: Open to the public Wednesday,
March 30, 2022 from 12:00 p.m. to 4:00
p.m. Eastern time.
ADDRESSES: The meeting will be held by
videoconference/teleconference. To
participate in the meeting, see the
Meeting Accessibility section for
instructions.
FOR FURTHER INFORMATION CONTACT:
CAPT Gregory H. Gorman, U.S. Navy,
703–275–6060 (voice),
gregory.h.gorman.mil@mail.mil (email).
Mailing address is 7700 Arlington
Boulevard, Suite 5101, Falls Church,
Virginia 22042. Website: http://
www.health.mil/dhb. The most up-todate changes to the meeting agenda can
be found on the website.
SUPPLEMENTARY INFORMATION: This
meeting is being held under the
provisions of the Federal Advisory
Committee Act (FACA) (5 U.S.C.), the
SUMMARY:

PO 00000

Frm 00029

Fmt 4703

Sfmt 4703

13279

Government in the Sunshine Act of
1976 (5 U.S.C. 552b), and 41 CFR 102–
3.140 and 102–3.150.
Availability of Materials for the
Meeting: Additional information,
including the agenda, is available at the
DHB website, http://www.health.mil/
dhb. A copy of the agenda or any
updates to the agenda or the March 30,
2022, meeting will be available on the
DHB website. Any other materials
presented in the meeting may be
obtained at the meeting.
Purpose of the Meeting: The DHB
provides independent advice and
recommendations to maximize the
safety and quality of, as well as access
to, health care for DoD health care
beneficiaries. The purpose of the
meeting is to provide briefings to DHB
members on current issues related to
military medicine and upcoming DHB
taskings.
Agenda: The DHB meeting will be
called to order and begin with both
opening and administrative remarks at
noon. At 12:30 p.m. the discussion will
move to mental health care access and
recess at 1:30 p.m. for a 15-minute
break. At 1:45 p.m., the DHB will
discuss racial and ethnic health care
disparities and then at 2:45 p.m.
conclude with a discussion on virtual
health in the Military Health System.
After closing remarks at 3:45 p.m., the
meeting will adjourn at 4:00 p.m. Any
changes to the agenda can be found at
the link provided in this SUPPLEMENTARY
INFORMATION section.
Meeting Accessibility: Pursuant to 5
U.S.C. 552b and 41 CFR 102–3.140
through 102–3.165, this meeting is open
to the public from 12:00 p.m. to 4:00
p.m. on March 30, 2022. The meeting
will be held by videoconference/
teleconference. The number of
participants is limited and is on a firstcome basis. All members of the public
who wish to participate must register by
emailing their name, rank/title, and
organization/company to
dha.ncr.dhb.mbx.defense-healthboard@mail.mil or by contacting Ms.
Pamela Shell at (703) 275–6012 no later
than Wednesday, March 23, 2022. Once
registered, the web address and audio
number will be provided.
Special Accommodations: Individuals
requiring special accommodations to
access the public meeting should
contact Ms. Pamela Shell at least five (5)
business days prior to the meeting so
that appropriate arrangements can be
made. Written Comments and
Statements: Any member of the public
wishing to provide comments to the
DHB related to its current taskings or
mission may do so at any time in
accordance with section 10(a)(3) of the

E:\FR\FM\09MRN1.SGM

09MRN1